久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

上海非利加實業有限公司Logo

熱門詞: 進口電動溫度調節閥結構圖|進口電動溫度調節閥數據表進口電動高溫調節閥-德國進口電動高溫法蘭調節閥進口電動蒸汽調節閥-德國進口電動蒸汽調節閥

當前位置: 首頁 > 所有品牌 > Pulmatrix
Pulmatrix
Pulmatrix Pulmatrix

美國Pulmatrix  
Pulmatrix公司,一個臨床階段的生物制藥公司,開發用于治療,預防和傳輸控制的傳染病和進步呼吸系統疾病的吸入療法。它提供吸入呼吸道襯調制陽離子藥物,刺激呼吸道內的宿主防御機制來治療和預防流感,鼻病毒,慢性肺疾病。該公司成立于2003年,總部設在美國馬薩諸塞州列克星敦。

Pulmatrix is a clinical stage biotechnology company with an inhaled dry powder platform advancing a new generation of inhaled therapeutics. The platform, called iSPERSE (inhaled small particles easily respirable and dispersible), represents a new paradigm in inhaled drug delivery based on unique properties: dense, high drug load engineered particles with highly efficient dispersibility and delivery to the airways. The iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance including our novel iCALM (inhaled Cationic Airway Lining Modulators) therapies, small molecules, biologics, and multi-drug combinations.

With the iSPERSE platform, Pulmatrix is developing a broad pipeline to prevent and treat a range of respiratory diseases with significant unmet medical needs including chronic obstructive pulmonary disease (COPD), cystic fibrosis, idiopathic pulmonary fibrosis, and severe asthma. The company has demonstrated comprehensive data showing that iSPERSE can be applied to a broad range of therapeutic compounds ranging from small molecules to proteins and including our lead dry powder iCALM therapies. Further optimization of select iSPERSE therapeutic formulations across a range of drug loads for scale up, manufacturing conditions, and stability testing has yielded promising results for the potential of the platform. Potential advantages of iSPERSE platform therapeutics on clinical treatment efficacy include reduced total inhaled powder mass, enhanced dosing efficiency, reduced cost of goods and improved safety and tolerability profiles.

Proprietary iCALM therapies comprise combinations of cationic salts designed to trigger multiple mechanisms that harness the body’s natural host defense and immune response in the airway to reduce inflammation, safely prevent and treat respiratory infections, and prevent acute exacerbations in patients with chronic inflammatory airway disease. The company’s lead dry powder iCALM drug candidate is the first clinical candidate based upon the iSPERSE platform. A host-targeted therapy, iCALM is designed to have broad application for respiratory diseases such as COPD, asthma, and cystic fibrosis and respiratory infections including influenza, influenza-like illness (ILI), rhinovirus, ventilator associated pneumonia (VAP) and respiratory syncytial virus (RSV). Pulmatrix has successfully completed Phase 1 safety and tolerability testing of our lead dry powder iCALM drug candidate in human studies including allergic asthmatics and COPD patients. The company has active clinical programs in COPD and cystic fibrosis.

關于我們客戶服務產品分類法律聲明
主站蜘蛛池模板: 日韩欧美区| 日本人乱人乱亲乱色视频观看 | 亚洲图片国产日韩欧美 | 69国产成人综合久久精品91 | 国产最新进精品视频 | 亚洲精品国产第七页在线 | 亚洲精品影院久久久久久 | 久久伊人一区二区三区四区 | 日韩精品电影在线观看 | 亚洲欧美自拍偷拍 | 欧美精品国产综合久久 | 国产浴室偷窥在线播放 | 一区精品在线 | 亚洲一区 中文字幕 久久 | 国产欧美久久久精品影院 | 国产成人a一区二区 | 91大神在线精品视频一区 | 欧美一区二区在线观看免费网站 | 日韩免费一区二区三区在线 | 免费视频二区 | 国产不卡一区二区视频免费 | 久久久午夜 | 国产第八页 | 久久久久久国产a免费观看黄色大片 | 精品欧美一区二区三区在线观看 | 日韩成人在线视频 | 日韩欧美专区 | 日本一区二区三区不卡在线视频 | 国产精品成人一区二区 | 国产图区| 欧美a色爱欧美综合v | 欧美性xxxx| 欧美激情hd | 欧美日韩大尺码免费专区 | 国产福利一区二区三区 | 91麻豆精品| 亚洲欧洲另类 | 欧美喷水| 亚洲韩国日本欧美一区二区三区 | 亚洲国产精品一区二区久久 | a级精品国产片在线观看 |